The Live Nagpur
  • Nagpur City
  • Nagpur Education
  • Nagpur Sports
  • Business
  • Featured
  • Crime
  • Entertainment & Lifestyle
  • Health & Wellness
  • Nation
  • Politics
  • Trending
  • Vidarbha
  • Obituary

The Live Nagpur


  • Home
  • City
  • Politics
  • Business
  • Education
  • Entertainment
  • Sports
  • Health
  • Crime
  • Forest
  • Featured
  • Vidarbha
Health & Wellness

COVID-19: Hetero and Cipla get India’s drug regulator nod for antiviral drugs Remdesivir

by TLN Team June 21, 2020
written by TLN Team June 21, 2020
COVID-19: Hetero and Cipla get  India’s drug regulator nod for antiviral drugs Remdesivir

Another good news for India who has been fighting with the deadly Coronavirus from the past 3 months as Hetero and Cipla have been given a nod by India’s drug regulator to manufacture and market antiviral drugs Remdesivir for “restricted emergency use” on hospitalised Covid-19 patients.

“The approval to Hetero and Cipla was given on Saturday,” news agency PTI quoted a source as saying.

With this written informed consent of each patient is required before the use of remdesivir and results of additional clinical trials, active post-marketing surveillance data, and reporting of serious adverse events have to be submitted.

The Union health ministry, in its ‘Clinical Management Protocols for COVID-19’, recommended the use of remdesivir on patients in the moderate stage of the disease that is, those on oxygen.

The drug has been included as an “investigational therapy” only for restricted emergency use purposes.

Gilead Sciences had applied to the Indian Drug Regulatory Agency, Central Drug Control Standard Organisation (CDCSO), for import and marketing of remdesivir on May 29. After due deliberations, permission under emergency use authorisation was granted by DCGI on June 1 in the interest of patient safety and obtaining further data.

Although Cipla and Hetero have not officially confirmed the news.

Recently Glenmark becomes the first pharmaceutical company in India to receive regulatory approval for oral antiviral Favipiravir, for the treatment of mild to moderate COVID-19. The drug will be available as a prescription-based medication for Rs 103/tablet, with recommended dose being 1800 mg twice daily on day 1, followed by 800 mg twice daily up to day 14.

0 comment
FacebookTwitterLinkedin
TLN Team

previous post
Decriminalising Bouncing of Cheques will Increase Hardship: Dipen Agrawal, President-CAMIT
next post
CAIT sought support of chief ministers of all states for its boycott Chinese goods campaign

You may also like

Retirement age limit of Public health docs reduced...

May 13, 2022

Diet counselling for children with special needs on...

May 12, 2022

Technology can make India self-reliant: Dr Sonde

May 12, 2022

Taking Care of Nutrition Needs of Kids with...

May 11, 2022

Knee replacement surgeries started under the MJPJAY scheme...

May 11, 2022

Vaccination: The Key to Preventing Influenza Infections amongst...

April 27, 2022

DCGI grants emergency use of Covaxin, Corbevax vaccine...

April 26, 2022

Wockhardt Hospital’s Personalized Cancer care bringing a revolutionary...

April 23, 2022

India logs 2,183 new cases, 214 deaths

April 18, 2022

Vihaan needs Rs 16 crore for treatment of...

April 16, 2022

Trending News

  • Rohit Sharma, K L Rahul to be rested for T20 series

    May 15, 2022
  • Australian Cricket Star Andrew Symonds Dies In Car Crash

    May 15, 2022
  • Rainfall in 15 States till 18th May: IMD Alert

    May 14, 2022
  • Helicopter Crash At Airport In Raipur, 2 Pilots Dead

    May 13, 2022
  • Tibet plane catches fire at China airport, no casualty reported

    May 12, 2022

Important Links

  • Politics
  • Crime
  • Business
  • Education
  • Entertainment
  • Sports

Available on Playstore & Coming Soon on Appstore

Search

June 2020
M T W T F S S
« May   Jul »
1234567
891011121314
15161718192021
22232425262728
2930  

Sign-Up Form

Subscribe my Newsletter for new blog posts, tips & new photos. Let's stay updated!

Footer Logo
  • Nagpur City
  • Nagpur Education
  • Nagpur Sports
  • Business
  • Featured
  • Crime
  • Entertainment & Lifestyle
  • Health & Wellness
  • Nation
  • Politics
  • Trending
  • Vidarbha
  • Obituary
  • Privacy Policy
  • Disclaimer
  • Cookie Policy
  • Terms Of Use
  • Advertise with Us
  • Work with us
  • Contact Us

© 2020 - The Live Nagpur . All Rights Reserved.